Pfizer's Nyvepria helps to reduce the chance of infection due to a low white blood cell count in people with non-myeloid cancer who receive anti-cancer medicines, including chemotherapy.
The Oseltamivir phosphate brand and generic had a market value of roughly $188 million, while the dofetilide brand and generic had a market value of more than $63.4 million.